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ABSTRACT
Aims: To review the present knowledge about congenital toxoplasmosis in South America and to advance some 
hypothesis for future research. Source of data: Medline and Scielo database search for papers reporting clinical 
characteristics of cohorts of children in South America and comparative studies between South America and other 
continents. Summary of findings: Systematic analysis of primary data obtained during screening programs showed 
that the risk of ocular lesions in congenital toxoplasmosis was much higher in the South American cohorts (47%; 18/38) 
than in Europe (14%, 79/550). The crude risk of intracranial lesions was much higher in the cohorts from South America 
(53%, 20/38) than those from Europe (9%, 49/550). In a Colombian cohort it was found 11% of mortality. Additionally, a 
comparative prospective cohort of congenitally infected children from Brazil and Europe found that in Brazilian children 
eye lesions were larger, more numerous and more likely to affect the area of the retina responsible for central vision that 
their counterpart in Europe. The presence of Toxoplasma strains genetically different to those found in North America 
and Europe could explain the higher severity of congenital toxoplasmosis in South America. Conclusions: Congenital 
toxoplasmosis in South America seems to be more frequent and infected children are more symptomatic than in Europe 
and in North America. Research for new drugs and candidate vaccines are a priority to improve indicators of health in 
children of South America.
Keywords: Toxoplasma gondii/genetics; Toxoplasma gondii/pathogenicity; Toxoplasma gondii/classification; POLYMORPHISM, 
GENETIC; GENETIC PREDISPOSITION TO DISEASE; TOXOPLASMOSIS, CONGENITAL/epidemiology; TOXOPLASMOSIS, 
CONGENITAL/complications;  TOXOPLASMOSIS,  CONGENITAL/virulence;  TOXOPLASMOSIS,  CONGENITAL/mortality; 
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RESUMO
Objetivos: revisar o conhecimento atual sobre toxoplasmose congênita na América do Sul e traçar algumas 
hipóteses para futura pesquisa. Fonte de dados: busca nas bases de dados Pubmed e Scielo por artigos sobre 
características clínicas de coortes de crianças com toxoplasmose congênita na América do Sul e estudos com 
parativos entre América do Sul e outros continentes. Síntese dos dados: uma análise sistemática de dados primários 
obtidos durante programas de triagem mostrou que o risco de lesões oculares foi muito maior na coorte de crianças 
da América do Sul (47%, 18/38) do que nas européias (14%, 79/550). O risco bruto de lesões intracranianas foi 
muito maior na coortes da América do Sul (53%, 20/38) do que nas da Europa (9%, 49/550). Em uma coorte 
colombiana constatou-se 11% de mortalidade. Adicionalmente, uma coorte prospectiva, que comparou crianças com 
toxoplasmose congênita do Brasil e da Europa, mostrou que nas crianças brasileiras as lesões oculares foram maiores, 
mais numerosas e com maior probabilidade de atingir o polo posterior da retina do que nas européias. A presença 
de cepas de Toxoplasma gondii diferentes das da Europa e dos Estados Unidos pode explicar a maior gravidade da 
toxoplasmose congênita na América do Sul. Conclusões: a toxoplasmosis congênita na América do Sul parece ser 
mais frequente e as crianças infectadas são mais sintomáticas do que na Europa e na América do Norte. A pesquisa 
sobre novas drogas e vacinas deve ser prioritária, para melhorar os indicadores de saúde nas crianças da América 
do Sul.
Descritores: Toxoplasma gondii/genética; Toxoplasma gondii/patogenicidade; Toxoplasma gondii/classificação; POLIMORFISMO 
GENÉTICO; PREDISPOSIÇÃO GENÉTICA PARA DOENÇA; TOXOPLASMOSE CONGÊNITA/epidemiologia; TOXOPLASMOSE 
CONGÊNITA/complicações;  TOXOPLASMOSE  CONGÊNITA/virulência;  TOXOPLASMOSE  CONGÊNITA/mortalidade; 
TOXOPLASMOSE OCULAR; SINAIS E SINTOMAS; AMÉRICA DO SUL; COLÔMBIA; BRASIL104  Sci Med. 2010;20(1):103-107
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INTRODUCTION
Congenital toxoplasmosis occurs as a consequence 
of transplacental transmission of the protozoan parasite 
Toxoplasma gondii after a primary infection during 
pregnancy.1 Placental transmission is less frequent when 
infection is acquired before the tenth week of pregnancy 
and is very rare when infection is acquired before 
conception. In immunocompetent mothers who have 
been infected by Toxoplasma gondii before conception, 
the immune mechanisms prevent transmission of the 
infection to their fetuses, although there are exceptional 
reports of transmission during chronic infection (six 
in total).2 Public health programs for diagnosis and 
treatment of toxoplasmosis during pregnancy were 
established in France and in other European countries to 
detect and to treat primary infection. Another strategy, 
also first established in some European countries, is 
the newborn screening program.3 In other continents 
the neonatal strategy was first evaluated in the region 
of New England in the United States,4 then in Brazil,5-8 
and more recently in Colombia.9,10 As a consequence 
of the implementation of these programs in different 
continents, it was possible to obtain comparable clinical 
data of congenital toxoplasmosis, which resulted in 
an unexpected difference in severity between South 
American  and  European  cohorts. The  aim  of  this 
review is to summarize the new knowledge afforded 
by theses studies and to advance some hypothesis for 
future research work. 
REVIEW OF PUBLICATIONS
A review of the literature was conducted using 
the databases Medline and Scielo, covering the years 
1970-2009. MESH terms used were ‘Toxoplasma’, 
‘congenital  toxoplasmosis’,  ‘epidemiology’  and 
‘South America’. Articles  in  English  and  Spanish 
were included. Other articles were identified from the 
reference lists of articles found by the PubMed search. 
Articles were analyzed depending of the method of 
recruitment.  Hence,  analysis  is  made  differently 
for  children  referred  to  the  tertiary  level  hospital 
and for those detected during neonatal and prenatal 
screening.
Congenital toxoplasmosis in cohorts of referred 
South American children
All  South American  reports  have  trends  for  a 
high prevalence of symptomatic children in referred 
patients.11-14 A  clinical  consultation  for  congenital 
toxoplasmosis was open in September 2000 at the 
University of Quindio, located in the Center-Western 
region  of  Colombia  (534,552  inhabitants,  7,734 
liveborn infants in 2006).11 As prenatal program is 
recent in the region of Quindio and there are multiple 
administrative  barriers  for  prenatal  treatment,  a 
natural history of untreated infection was obtained 
for a significant number of cases. During this time, 
25 congenitally infected children were referred to 
the consultation from Quindio and other regions in 
Colombia, for confirmation of diagnosis and treatment. 
At the end of the first year of life, 57% of cases in 
this cohort had ocular involvement and 64% of cases 
had neurological involvement.11 Other reports in South 
America described clinical symptoms in referred cases 
to tertiary level hospitals in similar percentage of ocular 
and neurological involvement. In Chile, in 11 of 15 
(73.3%) symptomatic children, ocular manifestation 
was  present.12  In  Brazil,  in  43  children,  77%  had 
neuroradiological  alterations,  and  retinochoroiditis 
was found in 95% of cases.13 
Frequency and clinical severity of  
congenital toxoplasmosis in cohorts detected 
during neonatal and prenatal screening in 
South America compared to other  
geographical regions
The  frequency  of  congenital  toxoplasmosis  as 
determined by newborn screening programs in South 
America varies in rates of 0.6% reported in Colombia 
to 0.01% in some regions of Brazil (Table 1).5-11 This 
frequency is at least 10 times higher in most of the 
studies performed in South America than in those 
reported in Europe and United States.15,16
The  frequency  of  primary  infection  during 
pregnancy  in  Colombia  has  been  established  by 
mathematical models in a representative sample in a 
national study in 1980, then in the Quindio region in 
1993, and by a new analysis in this same region in 
2002.17 These analyses showed that age related change 
in prevalence was the same at the national and regional 
levels and that it were unchanged between 1993 and 
2002. This revealed that women in the group of 10-15 
years of age had an annual risk of 1.5% whereas the risk 
in women of 35-40 years was 0.4%. This information 
is now more relevant because teenage pregnancy has 
importantly risen during the last years in Colombia 
and represent near of 20% of new pregnant women 
(13% in 1990, 17% in 1995 and 19% in 2000).18 
As a result of that study, prenatal programs were 
initiated in the public and private health services.11 
In addition, two pilot programs of newborn screening 
were performed in 20039 and in 2004.10 In an analysis 
of 17 children congenitally infected and detected in 
prenatal and neonatal screening programmes, 41%   Sci Med. 2010;20(1):103-107  105
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were symptomatic, of whom seven received prenatal 
in utero treatment.11 Four of 13 children (30%) had 
retinochoroidal lesions, and four of 11 (36%) had 
neurological involvement (in ultrasound examination). 
Two children (11.7%) died before six months of age.11 
Besides the high prevalence, congenital cases in 
South America  are  more  symptomatic. The  higher 
severity of South American cases was an unexpected 
result  of  the  Systematic  Review  on  Congenital 
Toxoplasmosis (SYROCOT) international collaborative 
study.19 For this analysis, 25 cohorts of infected mothers 
identified during prenatal screening were selected. 
The risk of ocular lesions was much higher in the 
South American cohorts (47%; 18/38) than in Europe 
(14%, 79/550). The crude risk of intracranial lesions 
detected  by  cerebral  tomography  scan  was  much 
higher in the cohorts from North (19%, 19 of 103) 
and South America (53%, 20 of 38) than those from 
Europe (9%, 49 of 550), where cranial ultrasound was 
used. Another finding was that the risk of transmission 
decreased significantly with higher latitude (odds ratio 
[OR]=0.71 for 5° higher, 95% confidence interval 
[CI] 0.53-0.96). Theses results were then confirmed 
by a comparative prospective cohort of children with 
congenital  toxoplasmosis  identified  by  universal 
neonatal screening in Brazil and neonatal or prenatal 
screening in Europe between 1992 and 2003, using the 
same protocol in both continents.20 The median follow 
up was 4.1 years in Europe and 3.7 years in Brazil. 
Relatively more children had retinochoroiditis during 
the first year in Brazil than in Europe: 15/30 (50%) 
versus 29/281 (10%). The risk of lesions by four years 
of age was much higher: the hazard ratio for Brazil 
versus Europe was 5.36 (95% CI 3.17-9.08). Children 
in Brazil had larger lesions, which were more likely to 
be multiple and to affect the posterior pole. In Brazil, 
visual impairment was predicted for most affected 
eyes (87%, 27/31), but not in Europe (29%, 20/69); 
p=0.0001. Therefore, the results of that study showed 
that Brazilian children had a five times higher risk than 
European children of developing eye lesions, and their 
lesions were larger, more numerous and more likely 
to affect the area of the retina responsible for central 
vision.20 Also, in a maternal screening in 2,513 mothers 
during delivery, in Rio Grande do Sul, Brazil, all the 
three infected newborns were symptomatic with active 
ocular lesions.21 Altogether, these reports of children 
detected  during  prenatal  and  newborn  screening 
confirm a higher percent of symptomatic children in 
South America. 
New world and old world strain types of 
toxoplasma: relevant for congenital infection?
Recent  findings  about  the  genetic  diversity  of 
Toxoplasma have revealed the extraordinary structure of 
this successful parasite, and at the same time generated 
a debate about the origin of the parasite and about what 
markers would be useful to its genetic typing. Many 
studies revealed that strains from South America are 
genetically distinct from strains from North America 
and Europe.22 This conclusion was first obtained by 
using a “SAG2 clonal genotype classification” of type 
I, type II and III23 and then confirmed by multilocus 
analysis24 and by serogenotyping, which identifies 
specific antibodies for clonal lineages I, II and III.25 
The  three  clonal  lineages  classified  by  using 
the SAG2 genotyping can be found indistinctly in 
congenital or in immunosupressed patients.23 Thus, 
SAG2 genotyping is not useful for clinical correlates, 
but it was the first technique that demonstrated different 
genetic structure between New World and Old World 
Toxoplasma. Also, methods that classify strains by 
serotypes of clonal lineages failed to demonstrate a 
clinical correlate with ocular toxoplasmosis, but remains 
Table 1. Prevalence of congenital toxoplasmosis in South American newborn screening programs.
Place of the study Number of screened 
newborns Assay Prevalence (%) CI 95% Author (Year)
Brazil (all states) 364,130 IgM FEIA 0.05 0.05-0.05 Neto et al (2004)5
Uberlândia, Minas 
Gerais, Brazil
805 IgM-IgA EIA 0.50 0.1-0.9 Segundo et al. (2004)6
Riberão Preto, São 
Paulo, Brazil
15,162 IgM FEIA 0.03 0.01-0.07 Carvalheiro et al. 
(2004)7
Porto Alegre, Rio 
Grande do Sul, Brazil
10,000 IgM FEIA 0.06 0.02-0.13 Lago et al. (2007)8
Quindio, Reference 
Hospital (Colombia)
200 IgM-IgA Western blot 0.50 0.2-0.8 Gallego-Marin et al 
(2006)9
Quindio, Community 
Hospital, Colombia
322 IgM EIA 0.62 0.19-2.2 Gomez-Marin et al. 
(2007)10
Cordoba, Argentina 673 Persistence of IgG one 
year after birth
0.45 0.18-0.72 Del Vado et al (1997)14106  Sci Med. 2010;20(1):103-107
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strongly linked to geographical origin.25 Therefore, 
it is essential to precisely define the questions to be 
resolved by each genetic marker (Table 2).
Limits of parasite genotyping on clinical 
samples and future work
A significant problem to analyze the relation of 
the Toxoplasma genotype with clinical outcome and 
prognosis in human infection is the difficulty of studying 
the parasite on clinical samples. The most important 
series of genotyping of Toxoplasma strains on clinical 
samples of congenital toxoplasmosis were performed 
in Europe in 86 samples26 and in South America in 
6 Colombian samples.23 The use of genetic markers 
in clinical samples could be challenging. Negative 
amplification was described when the genotyping was 
tried directly from clinical samples. In Colombia, a 
SAG2 genotyping was only possible in 33 of 50 (66%) 
clinical and animal positive samples for B1 specific 
Toxoplasma gene.23 For SAG2 genotyping, a restriction 
fragment length polymorphism (RFLP) analysis is 
made on two products of amplifications, one for the 3’ 
end and another for the 5’ end. In the Colombian study, 
no amplification of 3’ end was found in 19 samples 
(57%) and no amplification of 5’ end fragments was 
found in three samples (9%). This can be explained 
by presence of polymorphisms in the primers binding 
site of these isolates. The low sensitivity of these 
markers could be due to the fact that the target (SAG-2 
gene) is present in genome as a single copy, and to 
the low amount of parasite DNA present in clinical   
samples. 
Theses results on clinical samples showed the 
urgent need to find a sensitive genetic marker that 
could be applied for clinical studies. When looking for 
accurate genetic markers of parasite virulence, a genetic 
analysis of the whole Toxoplasma genome showed a 
virulence trait that explained the high virulence of 
the type I lineages in mouse and proved to be largely 
(90%) due to a single allele at the ROP18 locus, a 
gene encoding a rhoptry protein kinase.27 However, the 
clinical significance for human is unknown. 
Additionally  to  these  important  barriers  for 
the  application  of  parasite  genotyping  in  human 
infection, there are some crucial questions about the 
contribution of host and parasite factors in human 
Toxoplasma infection. This is a critical point to be 
defined  before  the  implementation  of  Toxoplasma 
genotyping  for  clinical  application  (i.e.  to  define 
prognosis of a patient). Not all children who acquire 
infection in utero develop clinical signs of disease. 
Whilst severity of disease is influenced by trimester 
in which infection is acquired by the mother, other 
factors, including genetic predisposition and parasite 
strain, may also contribute. This has become now more 
relevant by the discovery of the association of ocular 
and brain disease in congenital toxoplasmosis with 
parental polymorphisms in ABCA4 encoding ATP-
binding cassette transporter, subfamily A, member 4. 
Polymorphisms at COL2A1 encoding type II collagen 
are associated only with ocular disease. Both loci 
showed unusual inheritance patterns for the disease 
allele  when  comparing  outcomes  in  heterozygous 
affected children with outcomes in affected children 
of heterozygous mothers.28 Therefore, the genotyping 
of the parasite is not enough to define the outcome of 
a congenital infection.
In  this  context,  genotyping  studies  applied  on 
clinical samples are now needed, but it would be 
necessary  to  determine  if  the  detection  of  ROP8 
insertion/deletion polymorphism is better correlated 
with clinical outcome than the markers used so far. 
Future clinical application of genotyping in congenital 
toxoplasmosis should also define the relative weight of 
genetic susceptibility (ABCA4 and COL2A1 genotypes 
in the host) and parasite strain (i.e. ROP18 insertion/
deletion), by improving the sensitivity of amplification 
methods for parasite DNA targets.
CONCLUSIONS AND PROSPECTS FOR 
RESEARCH IN SOUTH AMERICA
In conclusion, congenital toxoplasmosis in South 
America is a public health problem with a significant 
Table 2. Practical application of genotype markers of Toxoplasma gondii.
Marker Origin of the 
species
Clonal groups versus 
non clonal groups Clinical correlate Mouse virulence
Geographical divergence 
(South America versus 
North America and Europe)
SAG2 No No No No Yes
Microsatellites ? No No No Yes
Introns ? Yes No No Yes
ROP18 Polymorphism No No ? Yes No
Mitochondrial or 
apicoplast sequences
? 
Probably yes No ? 
Probably no
? 
Probably no
? 
Probably no  Sci Med. 2010;20(1):103-107  107
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impact on children morbidity and mortality. Research 
for new drugs and candidate vaccines are a priority 
to improve indicators of health in South American 
children.  A  practical  consequence  of  the  higher 
frequency of symptomatic congenital toxoplasmosis 
in South American is that clinical trials to test new 
vaccine or therapeutic candidates would need smaller 
samples than in Europe. Altogether, these new data 
are  precious  to  address  the  research  in  this  field. 
Some issues to resolve include whether it is feasible to 
determine the strain type in clinical samples to predict 
the prognosis, and whether it is possible to identify 
virulence proteins for development of new drugs or 
vaccine approaches.
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